Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis

• Vincenzo C. Leo,
• Syed Kazmi,
• Jack Brownrigg,
• Marzieh Araghi,
• Harpreet S. Sarna,
• Pierpaolo Pellicori,
• Joe Cuthbert,
• John G.F. Cleland,
• Andrew L. Clark

Affiliations

Vincenzo C. Leo

Pfizer Ltd, Walton Oaks Dorking Rd Tadworth KT20 7NS UK

Syed Kazmi

Hull University Teaching Hospitals Trust, Castle Hill Hospital Castle Rd Cottingham HU16 5JQ UK

Jack Brownrigg

Pfizer Ltd, Walton Oaks Dorking Rd Tadworth KT20 7NS UK

Marzieh Araghi

Pfizer Ltd, Walton Oaks Dorking Rd Tadworth KT20 7NS UK

Harpreet S. Sarna

Pfizer Ltd, Walton Oaks Dorking Rd Tadworth KT20 7NS UK

Pierpaolo Pellicori

British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health University of Glasgow Glasgow UK G12 8QQ

Joe Cuthbert

Hull York Medical School Castle Hill Hospital Castle Rd, Cottingham Kingston upon Hull HU16 5JQ UK

John G.F. Cleland

British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health University of Glasgow Glasgow UK G12 8QQ

Andrew L. Clark

Hull University Teaching Hospitals Trust, Castle Hill Hospital Castle Rd Cottingham HU16 5JQ UK